Pharma News, 2022

The makers behind two of the largest COVID-19 vaccines, Pfizer, BioNTech, and Moderna, are seeking FDA approval for a fourth dose of their respective COVID-19 vaccines. Pfizer and BioNTech submitted a...

The UK’s National Institute for Health and Care Excellence (NICE) has recommended the routine use of BioMarin’s Vimizin (elosulfase alfa) by the National Health Service (NHS) for patients with ...

On March 18, 2022, FDA approved Bristol-Myers Squibb Company’s Opdualag (nivolumab and relatlimab-rmbw) for use in adults and pediatric patients 12 years of age or older with unresectable or meta...

Marinus Pharmaceuticals, a biopharmaceutical company focused on the development of treatments for seizure disorders, announced on March 18, 2022 that FDA has approved ZTALMY (ganaxolone) for the t...

Patients eligible to receive Takeda’s Exkivity (mobocertinib) have a rare form of lung cancer that cannot be removed by surgery

A newly reported study has provided more evidence that ivermectin is ineffective as a treatment for COVID-19 infection.

France’s highest court has ordered European drugmaker Merck KGaA to pay more than $3.6 million to patients who received a thyroid drug Levothyrox (levothyroxine sodium) with diminished quality f...

The United Nations-backed Medicines Patent Pool (MPP) has signed agreements with 35 companies to manufacture generic versions of Pfizer’s COVID-19 therapeutic Paxlovid (nirmatrelvir). ...

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative c...

Roche has published long-term data confirming the efficacy and safety of its drug Evrysdi (risdiplam) in patients age two to 25 who have type 2 or type 3 spinal muscular atrophy, a rare and often ...

Allarity Therapeutics, Inc. has filed a formal request with the FDA to hold a Type C meeting where they can discuss possible clinical paths to support the approval of dovitinib in renal cell carci...

Exelixis announced that it has scrapped plans to submit a supplemental new drug application (sNDA) for its cancer therapy Cabometyx (cabozantinib) for the treatment of newly diagnosed hepatocellul...